This morning while doing our normal web surfing we came across this piece of news;
“Since earning FDA clearance for its automated glucose monitoring system in 2017, OptiScan has introduced the device to select hospitals in the U.S. and Europe. Now, the company has raised $20 million in series E financing for a broader rollout of the system and to expand its platform to measure analytes other than glucose.”
Now we must admit this news caught us slightly off guard as we didn’t know that OptiScan was still in business. It also brought back memories of the very . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.